Literature DB >> 1900256

Therapy of chronic hepatitis C with alpha-interferon: the answer? Or more questions?

A M Di Bisceglie, J H Hoofnagle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1900256     DOI： 10.1016/0270-9139(91)90318-p

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  10 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  Chronic non-A, non-B hepatitis: role of hepatitis C virus.

Authors:  R Iorio; S Guida; S Porzio; I Fariello; A Vegnente
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

3.  Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha.

Authors:  J C Booth; G R Foster; U Kumar; R Galassini; R D Goldin; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

4.  Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

Authors:  K Kurokohchi; T Akatsuka; C D Pendleton; A Takamizawa; M Nishioka; M Battegay; S M Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials.

Authors:  Kelly De Kaita; Stephen Wong; Eberhard Renner; Gerald Y Minuk
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

6.  Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein.

Authors:  M Shirai; T Akatsuka; C D Pendleton; R Houghten; C Wychowski; K Mihalik; S Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

7.  Comparison among Different Types, Dosages and Duration of Interferon Therapy in Chronic Hepatitis C.

Authors:  G Bresci; G Parisi; S Metrangolo; M Bertoni; A Capria
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

Authors:  Y Kishihara; J Hayashi; E Yoshimura; K Yamaji; K Nakashima; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

9.  An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans.

Authors:  M Shirai; H Okada; M Nishioka; T Akatsuka; C Wychowski; R Houghten; C D Pendleton; S M Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

Authors:  J Camps; S Crisóstomo; M García-Granero; J I Riezu-Boj; M P Civeira; J Prieto
Journal:  Gut       Date:  1993-12       Impact factor: 23.059
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.